Abstract
In eukaryotes, the essential dimeric molecular chaperone Hsp90 is required for the activation and maturation of specific substrates such as steroid hormone receptors, tyrosine kinases and transcription factors. Hsp90 is involved in the establishment of cancer and has become an attractive target for drug design. Here we present a structural characterization of the complex between Hsp90 and the tumor suppressor p53, a key mediator of apoptosis whose structural integrity is crucial for cell-cycle control. Using biophysical methods, we show that the human p53 DNA-binding domain interacts with multiple domains of yeast Hsp90. p53 binds to the Hsp90 C-terminal domain in its native-like state in a charge-dependent manner, but it also associates weakly with binding sites in the middle and the N-terminal domains. The fine-tuned interplay between several Hsp90 domains provides the interactions required for efficient chaperoning of p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ali, M.M. et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440, 1013–1017 (2006).
Shiau, A.K., Harris, S.F., Southworth, D.R. & Agard, D.A. Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 127, 329–340 (2006).
Wandinger, S.K., Richter, K. & Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 283, 18473–18477 (2008).
Wegele, H., Wandinger, S.K., Schmid, A.B., Reinstein, J. & Buchner, J. Substrate transfer from the chaperone Hsp70 to Hsp90. J. Mol. Biol. 356, 802–811 (2006).
Fontana, J. et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. 90, 866–873 (2002).
Hawle, P. et al. The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol. Cell. Biol. 26, 8385–8395 (2006).
Meyer, P. et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell 11, 647–658 (2003).
Nathan, D.F. & Lindquist, S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol. Cell. Biol. 15, 3917–3925 (1995).
Harris, S.F., Shiau, A.K. & Agard, D.A. The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site. Structure 12, 1087–1097 (2004).
Hessling, M., Richter, K. & Buchner, J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 16, 287–293 (2009).
Park, S.J., Borin, B.N., Martinez-Yamout, M.A. & Dyson, H.J. The client protein p53 adopts a molten globule–like state in the presence of Hsp90. Nat. Struct. Mol. Biol. 18, 537–541 (2011).
Rudiger, S., Freund, S.M., Veprintsev, D.B. & Fersht, A.R. CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc. Natl. Acad. Sci. USA 99, 11085–11090 (2002).
Street, T.O., Lavery, L.A. & Agard, D.A. Substrate binding drives large-scale conformational changes in the hsp90 molecular chaperone. Mol. Cell 42, 96–105 (2011).
Römer, L., Klein, C., Dehner, A., Kessler, H. & Buchner, J. p53–a natural cancer killer: structural insights and therapeutic concepts. Angew. Chem. Int. Edn Engl. 45, 6440–6460 (2006).
Lane, D.P. & Crawford, L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261–263 (1979).
Linzer, D.I. & Levine, A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43–52 (1979).
Blagosklonny, M.V., Toretsky, J., Bohen, S. & Neckers, L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. USA 93, 8379–8383 (1996).
Wang, C. & Chen, J. Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J. Biol. Chem. 278, 2066–2071 (2003).
Whitesell, L. & Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761–772 (2005).
Müller, L., Schaupp, A., Walerych, D., Wegele, H. & Buchner, J. Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J. Biol. Chem. 279, 48846–48854 (2004).
Sepehrnia, B., Paz, I.B., Dasgupta, G. & Momand, J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J. Biol. Chem. 271, 15084–15090 (1996).
Nagata, Y. et al. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene 18, 6037–6049 (1999).
Whitesell, L., Sutphin, P.D., Pulcini, E.J., Martinez, J.D. & Cook, P.H. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol. 18, 1517–1524 (1998).
Piper, P.W. et al. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors. Gene 302, 165–170 (2003).
Richter, K. et al. Conserved conformational changes in the ATPase cycle of human Hsp90. J. Biol. Chem. 283, 17757–17765 (2008).
Dehner, A. et al. Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew. Chem. Int. Edn Engl. 44, 5247–5251 (2005).
Dehner, A. et al. NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. ChemBioChem 4, 870–877 (2003).
Salek, R.M., Williams, M.A., Prodromou, C., Pearl, L.H. & Ladbury, J.E. Backbone resonance assignments of the 25kD N-terminal ATPase domain from the Hsp90 chaperone. J. Biomol. NMR 23, 327–328 (2002).
Salzmann, M., Pervushin, K., Wider, G., Senn, H. & Wüthrich, K. TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. Proc. Natl. Acad. Sci. USA 95, 13585–13590 (1998).
Meyer, P. et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 23, 511–519 (2004).
Retzlaff, M. et al. Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol. Cell 37, 344–354 (2010).
Sugase, K., Dyson, H.J. & Wright, P.E. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 447, 1021–1025 (2007).
Wong, K.B. et al. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96, 8438–8442 (1999).
Battiste, J.L. & Wagner, G. Utilization of site-directed spin labeling and high-resolution heteronuclear nuclear magnetic resonance for global fold determination of large proteins with limited nuclear Overhauser effect data. Biochemistry 39, 5355–5365 (2000).
Cornilescu, G., Marquardt, J.L., Ottiger, M. & Bax, A. Validation of protein structure from anisotropic carbonyl chemical shifts in a dilute liquid crystalline phase. J. Am. Chem. Soc. 120, 6836–6837 (1998).
Hagn, F. et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J. Biol. Chem. 285, 3439–3450 (2010).
Tomita, Y. et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281, 8600–8606 (2006).
Friedler, A., Veprintsev, D.B., Rutherford, T., von Glos, K.I. & Fersht, A.R. Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J. Biol. Chem. 280, 8051–8059 (2005).
Wayne, N. & Bolon, D.N. Charge-rich regions modulate the anti-aggregation activity of Hsp90. J. Mol. Biol. 401, 931–939 (2010).
Walerych, D. et al. ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein. J. Biol. Chem. 285, 32020–32028 (2010).
Vaughan, C.K. et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23, 697–707 (2006).
Scheufler, C. et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 101, 199–210 (2000).
Fang, L., Ricketson, D., Getubig, L. & Darimont, B. Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Proc. Natl. Acad. Sci. USA 103, 18487–18492 (2006).
Yamada, S., Ono, T., Mizuno, A. & Nemoto, T.K. A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone. FEBS J. 270, 146–154 (2003).
Friedler, A. et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA 99, 937–942 (2002).
Richter, K., Muschler, P., Hainzl, O., Reinstein, J. & Buchner, J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the ATPase cycle. J. Biol. Chem. 278, 10328–10333 (2003).
Scheibel, T., Weikl, T. & Buchner, J. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc. Natl. Acad. Sci. USA 95, 1495–1499 (1998).
Ali, J.A., Jackson, A.P., Howells, A.J. & Maxwell, A. The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry 32, 2717–2724 (1993).
Schwarz, D. et al. Preparative scale expression of membrane proteins in Escherichia coli-based continuous exchange cell-free systems. Nat. Protoc. 2, 2945–2957 (2007).
Hayes, D.B. & Stafford, W.F. SEDVIEW, real-time sedimentation analysis. Macromol. Biosci. 10, 731–735 (2010).
Demeler, B. UltraScan: a comprehensive data analysis software package for analytical ultracentrifugation experiments. in Modern Analytical Ultracentrifugation: Techniques and Methods (eds. D.J. Scott, Harding, S.E. & Rowe, A.J.) 210–229 (Royal Society of Chemistry (UK), 2005).
Sattler, M., Schleucher, J. & Griesinger, C. Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients. Prog. Nucl. Magn. Reson. Spectrosc. 34, 93–158 (1999).
Jahnke, W., Bauer, C., Gemmecker, G. & Kessler, H. Improved accuracy of NMR structures by a modified NOESY-HSQC experiment. J. Magn. Reson. B. 106, 86–88 (1995).
Leutner, M. et al. Automated backbone assignment of labeled proteins using the threshold accepting algorithm. J. Biomol. NMR 11, 31–43 (1998).
Pervushin, K., Riek, R., Wider, G. & Wüthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA 94, 12366–12371 (1997).
Tjandra, N. & Bax, A. Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium. Science 278, 1111–1114 (1997).
Hansen, M.R., Mueller, L. & Pardi, A. Tunable alignment of macromolecules by filamentous phage yields dipolar coupling interactions. Nat. Struct. Biol. 5, 1065–1074 (1998).
Schwieters, C.D., Kuszewski, J.J., Tjandra, N. & Clore, G.M. The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 160, 65–73 (2003).
de Vries, S.J., van Dijk, M. & Bonvin, A.M. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5, 883–897 (2010).
García de la Torre, J., Huertas, M.L. & Carrasco, B. HYDRONMR: prediction of NMR relaxation of globular proteins from atomic-level structures and hydrodynamic calculations. J. Magn. Reson. 147, 138–146 (2000).
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft SFB594 and the Center for Integrated Protein Science Munich (J.B. and H.K.), the Elitenetzwerk Bayern (F.H. and J.R.) and the Fonds der chemischen Industrie (M.R.). F.H. is a recipient of an EMBO long-term fellowship (ALTF 265-2010). We want to thank D. Heckmann for peptide synthesis.
Author information
Authors and Affiliations
Contributions
F.H., S.L. and M.R. designed research, performed experiments, analyzed data and wrote the paper. J.R., O.D. and K.R. performed research and analyzed data. J.B. and H.K. designed research and wrote the paper. F.H. and S.L. carried out protein expression, interaction studies, resonance assignment, NMR interaction and docking studies. M.R. performed protein expression, interaction studies and activity assays.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 and Supplementary Table 1 (PDF 1125 kb)
Rights and permissions
About this article
Cite this article
Hagn, F., Lagleder, S., Retzlaff, M. et al. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol 18, 1086–1093 (2011). https://doi.org/10.1038/nsmb.2114
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb.2114
This article is cited by
-
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma
Cell Death & Disease (2024)
-
Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance
Cell Discovery (2023)
-
Molecular mechanisms and consequences of mitochondrial permeability transition
Nature Reviews Molecular Cell Biology (2022)
-
Structural elements in the flexible tail of the co-chaperone p23 coordinate client binding and progression of the Hsp90 chaperone cycle
Nature Communications (2021)
-
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells
Investigational New Drugs (2020)